Tags

Type your tag names separated by a space and hit enter

Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
J Clin Oncol 2008; 26(9):1519-25JC

Abstract

PURPOSE

The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation.

PATIENTS AND METHODS

Patients with MM (n = 109; mean age, 57 +/- 8 years) or NHL (n = 88; mean age, 50 +/- 13 years) were treated with high-dose melphalan (200 mg/m(2)) or carmustine 300 mg/m(2), etoposide 800 mg/m(2), cytarabine 800 to 1,600 mg/m(2), and melphalan 140 mg/m(2) chemotherapy, respectively, in 25 European centers. OM assessments were made daily until 30 days after transplantation or hospital discharge. High quality of OM assessment was ensured by an intensive training program.

RESULTS

Severe OM occurred in 46% (95% CI, 36% to 56%) of patients with MM and 42% (95% CI, 32% to 53%) of patients with NHL, with a mean duration of 5.3 days (95% CI, 4.4 to 6.1 days) and 5.5 days (95% CI, 4.5 to 6.7 days), respectively. Time from start of conditioning to peak OM score was 12.1 +/- 2.6 and 14.6 +/- 2.4 days. Severe OM risk and/or duration was significantly associated with higher chemotherapy dose per kilogram of body weight and poor performance status, but in contrast with some previous reports, this was not related to age.

CONCLUSION

Severe OM is more common in the transplantation setting than previously reported, justifying effective preventative and therapeutic measures.

Authors+Show Affiliations

Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands. n.blijlevens@hemat.umcn.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18268357

Citation

Blijlevens, Nicole, et al. "Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-dose Melphalan or BEAM Conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 26, no. 9, 2008, pp. 1519-25.
Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26(9):1519-25.
Blijlevens, N., Schwenkglenks, M., Bacon, P., D'Addio, A., Einsele, H., Maertens, J., ... McCann, S. (2008). Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 26(9), pp. 1519-25. doi:10.1200/JCO.2007.13.6028.
Blijlevens N, et al. Prospective Oral Mucositis Audit: Oral Mucositis in Patients Receiving High-dose Melphalan or BEAM Conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008 Mar 20;26(9):1519-25. PubMed PMID: 18268357.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group. AU - Blijlevens,Nicole, AU - Schwenkglenks,Matthias, AU - Bacon,Pamela, AU - D'Addio,Alessandra, AU - Einsele,Hermann, AU - Maertens,Johan, AU - Niederwieser,Dietger, AU - Rabitsch,Werner, AU - Roosaar,Ann, AU - Ruutu,Tapani, AU - Schouten,Harry, AU - Stone,Rebecca, AU - Vokurka,Samuel, AU - Quinn,Barry, AU - McCann,Shaun, AU - ,, Y1 - 2008/02/11/ PY - 2008/2/13/pubmed PY - 2008/3/28/medline PY - 2008/2/13/entrez SP - 1519 EP - 25 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 26 IS - 9 N2 - PURPOSE: The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation. PATIENTS AND METHODS: Patients with MM (n = 109; mean age, 57 +/- 8 years) or NHL (n = 88; mean age, 50 +/- 13 years) were treated with high-dose melphalan (200 mg/m(2)) or carmustine 300 mg/m(2), etoposide 800 mg/m(2), cytarabine 800 to 1,600 mg/m(2), and melphalan 140 mg/m(2) chemotherapy, respectively, in 25 European centers. OM assessments were made daily until 30 days after transplantation or hospital discharge. High quality of OM assessment was ensured by an intensive training program. RESULTS: Severe OM occurred in 46% (95% CI, 36% to 56%) of patients with MM and 42% (95% CI, 32% to 53%) of patients with NHL, with a mean duration of 5.3 days (95% CI, 4.4 to 6.1 days) and 5.5 days (95% CI, 4.5 to 6.7 days), respectively. Time from start of conditioning to peak OM score was 12.1 +/- 2.6 and 14.6 +/- 2.4 days. Severe OM risk and/or duration was significantly associated with higher chemotherapy dose per kilogram of body weight and poor performance status, but in contrast with some previous reports, this was not related to age. CONCLUSION: Severe OM is more common in the transplantation setting than previously reported, justifying effective preventative and therapeutic measures. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/18268357/Prospective_oral_mucositis_audit:_oral_mucositis_in_patients_receiving_high_dose_melphalan_or_BEAM_conditioning_chemotherapy__European_Blood_and_Marrow_Transplantation_Mucositis_Advisory_Group_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2007.13.6028?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -